Vernalis plc (VER) Given Average Rating of “Hold” by Analysts
Shares of Vernalis plc (LON:VER) have earned a consensus recommendation of “Hold” from the seven research firms that are presently covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is GBX 39.40 ($0.51).
Several research firms have recently commented on VER. Panmure Gordon reissued a “hold” rating and issued a GBX 31 ($0.40) price objective on shares of Vernalis plc in a report on Monday, August 7th. Stifel Nicolaus dropped their price target on Vernalis plc from GBX 24 ($0.31) to GBX 21 ($0.27) and set a “hold” rating on the stock in a research note on Monday, August 7th. N+1 Singer restated a “hold” rating and issued a GBX 28 ($0.36) price target on shares of Vernalis plc in a research note on Monday, August 7th. Finally, RX Securities restated a “buy” rating on shares of Vernalis plc in a research note on Monday, August 7th.
WARNING: “Vernalis plc (VER) Given Average Rating of “Hold” by Analysts” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/08/30/vernalis-plc-ver-given-average-rating-of-hold-by-analysts.html.
Vernalis plc (VER) traded down 5.43% during trading on Wednesday, hitting GBX 15.25. 5,000 shares of the stock were exchanged. Vernalis plc has a 12-month low of GBX 15.25 and a 12-month high of GBX 45.12. The firm’s market cap is GBX 80.27 million. The stock’s 50-day moving average price is GBX 17.55 and its 200-day moving average price is GBX 21.01.
About Vernalis plc
Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders.
Receive News & Stock Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related stocks with our FREE daily email newsletter.